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Abstract
Background: The World Health Organization has declared Sickle Cell Anemia (SCA) a public health priority. There are
300,000 births/year, over 75% in Africa, with estimates suggesting that 6 million Africans will be living with SCA if average
survival reaches half the African norm. Countries such as United States of America and United Kingdom have reduced SCA
mortality from 3 to 0.13 per 100 person years of observation (PYO), with interventions such as newborn screening,
prevention of infections and comprehensive care, but implementation of interventions in African countries has been
hindered by lack of locally appropriate information. The objective of this study was to determine the incidence and factors
associated with death from SCA in Dar-es-Salaam.
Methods and Findings: A hospital-based cohort study was conducted, with prospective surveillance of 1,725 SCA patients
recruited from 2004 to 2009, with 209 (12%) lost to follow up, while 86 died. The mortality rate was 1.9 (95%CI 1.5, 2.9) per
100 PYO, highest under 5-years old [7.3 (4.8–11.0)], adjusting for dates of birth and study enrollment. Independent risk
factors, at enrollment to the cohort, predicting death were low hemoglobin (,5 g/dL) [3.8 (1.8–8.2); p = 0.001] and high
total bilirubin ($102 mmol/L) [1.7 (1.0–2.9); p = 0.044] as determined by logistic regression.
Conclusions: Mortality in SCA in Africa is high, with the most vulnerable period being under 5-years old. This is most likely
an underestimate, as this was a hospital cohort and may not have captured SCA individuals with severe disease who died in
early childhood, those with mild disease who are undiagnosed or do not utilize services at health facilities. Prompt and
effective treatment for anemia in SCA is recommended as it is likely to improve survival. Further research is required to
determine the etiology, pathophysiology and the most appropriate strategies for management of anemia in SCA.
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Introduction
The greatest burden of sickle cell anemia (SCA) is in sub-Saharan
Africa (SSA), where 75% of the 300,000 global births of affected
children live[1], and estimates suggest that 50–80% of these patients
will die before adulthood[2]. The World Health Organization
estimate that 70% of SCA deaths in Africa are preventable with
simple, cost-effective interventions such as early identification of
SCA patients by newborn screening (NBS) and the subsequent
provision of comprehensive care. Identification of risk factors has
led to improved survival through targeted interventions. In the
West, reported risk factors for death include infections, low
hemoglobin and fetal Hb (HbF), high white blood cell count and
hemolysis[3–5]. Comprehensive care includes prompt treatment of
acute events and prophylaxis against infections, mainly with oral
penicillin and vaccination against Streptococcus pneumoniae. Countries
that have introduced these interventions have achieved significant
reductions in mortality; with up to 94% surviving to 18 years in the
United States of America (USA[6] and 99% to 20 years in the
UK[7]. In most African countries, the lack of an evidence-base has
led to inertia in terms of implementation of these interventions, such
as penicillin prophylaxis[8]. One of the first steps in addressing this
lack of knowledge is to provide an estimate of mortality rates to
highlight the burden of disease due to SCA. The ideal approach is to
establish a cohort of SCA patients, diagnosed at birth, and follow
them up to determine rate and cause of death. However, most
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countries in Africa do not have NBS programs, therefore such
evidence will rely on hospital-based studies. Information from such
cohorts is biased, as it will on one hand consist of healthy survivors
and on the other, will not identify those with mild disease who do
not seek healthcare or those with severe disease who have died. This
situation is similar to that in Jamaica and USA in the early 1970s,
when NBS for SCA was not established and evidence relied on
prospective studies in hospital-based cohorts, where most of the
patients (92% and 65% respectively) were not identified at
birth[4,9]. Despite the limitations of hospital-based studies, these
studies provided important evidence on morbidity and mortality
due to SCA.
In 2004, we established prospective surveillance of SCA patients
in a hospital in Tanzania. The frequency of the sickle
heterozygous carrier state (AS) in Tanzania is 13% with an
estimated annual births of 8,000 homozygous SS children,
compared to 302 in Jamaica and 1,500 in the USA[10]. The
overall aim of this study was to determine the burden of disease
due to SCA in Tanzania by describing the spectrum of disease.
Here, we report the rate and risk factors of mortality in Dar-es-
Salaam, Tanzania.
Methods
Study area
The study was conducted at Muhimbili National Hospital
(MNH), in Dar-es-Salaam, which is the administrative capital of
Tanzania with a population of 4 million. The hospital is the
national referral hospital but also serves as a first-level referral
hospital for all SCA patients in Dar-es-Salaam. MNH provides
health care to patients with SCA, where outpatient visits are
scheduled at three monthly intervals for routine check-up. All SCA
patients are prescribed folic acid (5 mg/day) and antimalarial
prophylaxis (chloroquine) as recommended by the National
Malaria Control Programme of Tanzania[11]. Penicillin prophy-
laxis is not part of standard care for SCA in Tanzania. There is no
NBS in Tanzania to identify SCA individuals at birth. As part of
the policy of Ministry of Health and Social Welfare of Tanzania,
patients with SCA receive free health care. This study was
integrated into the existing healthcare system with no attempts to
recruit SCA patients or alter the system for referral and
management.
Following institutional ethical approval (reference MU/RP/
AEC/VOL XI/33), written informed consent, in the local
language (Kiswahili), was obtained from parents or guardians of
children and from patients who were above 18-years old.
Procedures
Enrollment was done at outpatient clinic. At enrollment, a
detailed history and examination was recorded onto standardized
proformas. Blood samples were collected for a complete blood
count (Pentra 60, Horiba ABX, Kyoto, Japan), hemoglobin
electrophoresis (Helena, Sunderland, Tyne & Wear, UK), high
performance liquid chromatography (Bio-Rad, Hercules, CA,
USA) and biochemical analysis (Roche Cobas Mira, New York,
USA or Abbott Architect, New York, USA). Nucleated RBC could
not be differentiated from neutrophils by the haematology
analyzer. All the SCA patients attending the clinic followed the
existing clinical practice of referrals and diagnosis on the basis of
clinical suspicion or family history. The management (diagnosis
and treatment) followed the hospital guidelines, with no change in
the normal clinical practice.
SCA individuals with acute illness were managed in the
emergency medicine department or were hospitalized. During
episodes of acute illness, patients were encouraged to contact their
nearest health facility and follow the referral procedures through
the public health care system. The decision to admit SCA patients
was made by the attending clinician in the hospital casualty
department, following criteria set by MNH.
SCA patients who did not attend clinic for more than 12 months
were defined as defaulters and were actively contacted by
telephone or, for those residents in Dar-es-Salaam, visited at
home. Patients who were not found after three attempts of tracing
were considered to be lost to follow-up.
Statistical analysis
Data were analyzed using STATAv10 (StataCorp, College
Station, TX, USA). The population prevalence of SCA was
calculated from the enrolled SCA patients divided by the
population of each ward as estimated in population census done
in 2002. Wards are local government units, on which the census is
based.
The study period started at enrollment clinic visit and the end
was date of death or date last known to be alive. For patients who
died outside the hospital where date of death could not be
ascertained, we used the date of last hospital attendance. The
overall and age-specific incident rate of mortality was estimated.
This was calculated from the ratio of number of deaths divided by
the number of person years of observation (PYO), expressed as
mortality rates. The Cnaan and Ryan approach to data analysis
was used[12], which takes into account patients entering and
leaving the study cohort with the observation beginning after
disease onset, which in this case was at birth. According to this
method, a patient contributes to the population at risk for a given
death only if that patient is enrolled in the study at the age at
which death occurs. We modeled age at death rather than the
length of time from enrollment to death to determine life
expectancy, in an approach similar to that used by Platt et al[5].
The standardized mortality ratio was calculated from the age-
specific mortality rate in Dar-es-Salaam (source: Tanzania
national Bureau of statistics).
Data were summarized as means, medians or proportions.
Logistic regression was used to analyze factors at enrollment
associated with death, with results presented as odds ratios (ORs)
with 95% confidence intervals (95%CIs). Multivariable logistic
regression was used to identify independent associations with
death, using variables that had significant association (p,0.05) on
univariable analysis. For the SCA patients who died in hospital,
the clinical and laboratory findings were reviewed and likely cause
of death was ascertained.
Results
From March 2004 to March 2009, 1,725 (90.6%) people with
SCA were enrolled, from 1,903 identified. The geographical
distribution of registered SCA patients who live in Dar-es-Salaam
is shown in figure 1, with 3.5/1000 as the highest population
prevalence of registered cases.
Age at enrollment and duration of follow-up (Table 1)
The median age at enrollment was 8 years [inter quartile range
(IQR) 4–13] years, with the age distribution as follows: 169 (9.8%)
,2 years; 365 (21.2%) 2–4 years; 477 (27.7%) 5–9 years; 519
(30.1%) 10–19 years and 195 (11.3%) .20 years. There were 856
(49.6%) males, who were significantly younger than females [Odds
Ratio OR=0.97 (0.96, 0.99); p-value ,0.001]. Longitudinal
information was available for 1,564 (90.6%) patients with 4,482
PYO, as 161 patients had only one visit. The median follow-up
Mortality in SCA in Africa
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period was 2.9 years (IQR 1.1–4.6 years). Information on vital
status (alive or dead) was not available on 209 (12.1%) patients
who were lost to follow-up.
Mortality rate, age and place of death. Death occurred in
86 (5.7%) out of 1,516 patients; with only 20 (23.3%) occurring in
MNH. The overall mortality rate was 1.9 (95%CI 1.5, 2.9) per 100
PYO. Since only 2 deaths were recorded in 46 children who were
less than 2 years old at time of death or exit, the rate was
calculated in three age groups, with the highest rate in those below
5 years old (table 2). The corresponding standardized mortality
ratio was; 2.9 in children less than 5-years: 5.4 in children between
5–19 years and 1.1 in individuals 20 years and above.
Factors at enrollment associated with death and cause of
death in hospitalized SCA patients. Table 2 shows the
association between death and laboratory characteristics at
enrollment of 1,516 patients. On univariable analysis, the SCA
individuals who died had significantly lower hemoglobin and
higher total and conjugated bilirubin (Table 3). Figure 2 shows the
probability of survival depending on level of hemoglobin at
Figure 1. The geographical distribution of registered SCA patients who live in Dar-es-Salaam.
doi:10.1371/journal.pone.0014699.g001
Table 1. Age at enrollment, duration of follow-up and age at
death.
Mean (SD) Median IQR Range
Age at entry (years)
Male (n = 856) 8.8 (7.4) 7 9–15 0–41
Female (n = 869) 10.5 (8.5) 9 7–12 0–48
Duration of follow up (years)
Total (n = 1,564) 2.9 (1.7) 2.9 1.1–4.6 1 month to 5
Age at death (years) (n = 86)
Male (n = 44) 12.7 (8.9) 11 4.5–18 2–37
Female (n = 42) 11.8 (8.9) 12 4–16 1–43
doi:10.1371/journal.pone.0014699.t001
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enrollment. On multivariable analysis, hemoglobin [0.71 (0.59–
0.84); p,0.001] and total bilirubin were independently associated
with mortality [1.00 (1.00–1.01); p = 0.020]. Using categorical
values, severe anemia, hemoglobin ,5 g/dL [3.8 (1.8–8.2);
p = 0.001] and high total bilirubin, $102 mmol/L [1.7 (1.0–2.9);
p = 0.044] were significantly associated with mortality.
Discussion
This is the first study that presents rates and risk factors for
mortality in SCA in Africa, the continent with the greatest burden
of disease. The mortality in this cohort was 1.9 per 100 PYO
which is similar to 3 per 100 PYO reported from the USA before
use of penicillin prophylaxis[13–14], but is an order of magnitude
higher than the current incidence of 0.13 per 100 PYO reported
from the USA[4,6]. This rate is likely to underestimate the
mortality in most African settings, where resources such as skilled
health care workers, investigations and treatment options are
limited, since this study was conducted at a university teaching
hospital, in an urban environment, where SCA individuals have a
relatively higher socio-economic status with good access to health
care.
The highest incidence of death in this study was in the first 5
years of life. This is similar to reports from Jamaica and USA in
the 1980’ and 1990s, where the highest rate was reported between
1–3 years[3,15–17]. Evidence from previous research suggest that
infection is the most likely cause of death in this period, with the
proportion of deaths from infection reported to be 50% in the
USA[3,16], 28% in Jamaica[15,17] and 20% in Dallas[6]. The
prevention of pneumococcal infection with penicillin and the
introduction of pneumococcal conjugate vaccine has been shown
to be effective in reducing mortality[18–19] with improved
survival rates of 84% in Jamaica[17], 86% by 18 years in
Dallas[6] and 99% in London[7]. A recent review reported 42%
reduction in mortality in SCA in USA, 0 to 3 years old, between
two eras, 1995–1998 and 1999–2002[20]. There is compelling
justification for implementation of these interventions in Africa to
prevent deaths due to infections[8,21]. This study highlights the
high mortality and limited information on natural history of SCA
in first 5 years of life. There is a dearth of information from
children in early childhood as 2 deaths were recorded in 42
children in this age group and only 10% of this cohort was
enrolled when less than 2 years old. This could be the result of
children not coming to hospital because they are not symptomatic
but since, the mortality was highest in the under 5-years age group,
it is highly likely that many deaths occur in early childhood before
a SCA diagnosis is made. This supports the importance of early
identification of SCA children. Ideally, this should be at birth by
NBS, and pilot studies have shown that NBS is feasible in
Africa[22–24]. Thereafter, comprehensive care can be provided,
with active interventions to prevent infections in early childhood,
which is the most likely cause of death in this vulnerable
period[25,26].
Table 2. Mortality rates stratified by age at censoring or death.
Age (group) Number of patients Observation (yrs) Number of Deaths Mortality rate per 100 PYO (95%CI)
,5 years 243 303.0 22 7.3 (4.8–11.0)
5–19 years 1,053 3,325.6 47 1.4 (1.1–1.9)
.20 years 267 849.4 15 1.8 (1.1–2.9)
Total 1,564 4,482 85 1.9 (1.5–2.9)
Mortality rates for 1,564 SCA patients enrolled and with more than one clinic visit. The rates take into account date of birth and date of recruitment into the study.
doi:10.1371/journal.pone.0014699.t002
Table 3. Laboratory features at enrollment visit associated with survival in SCA patients.
Clinical features
Survived
(n=1,430; 94.3%)
Died
(n =86; 5.7%)
Odds Ratio
(95% CI) p
n n (%) or mean (SD) n n (%) or mean (SD)
Age at enrollment (years) 1,430 9.5 (7.8) 86 10.2 (8.6) 1.01 (0.98–1.04) 0.408
White blood cell count (x109/L) 1,307 15.9 (6.9) 78 15.7 (7.3) 0.99 (0.96–1.03) 0.849
Hemoglobin (g/dL) 1,306 7.6 (1.3) 79 6.9 (1.6) 0.73 (0.62–0.86) ,0.001
Mean Corpuscular volume (fL) 1,298 79.2 (9.5) 77 79.5 (10.9) 1.00 (0.98–1.03) 0.752
Reticulocyte (% of RBC) 832 12.6 (7.1) 33 13.1 (8.6) 1.01 (0.96–1.06) 0.670
Hemoglobin F (%) 1,297 6.3 (4.7) 63 6.6 (4.9) 1.02 (0.96–1.07) 0.575
Total Bilirubin (mmol/L) 1,263 69.7 (56.7) 79 87.5 (81.4) 1.00 (1.00–1.01) 0.010
Direct Bilirubin (mmol/L) 1,157 20.9 (34.2) 72 33.1 (57.6) 1.00 (1.00–1.01) 0.019
Indirect Bilirubin (mmol/L) 1,140 51.5 (53.6) 71 57.1 (60.4) 1.01 (0.99–1.01) 0.396
Lactate dehydrogenase (IU/L) 559 965.4 (483.7) 27 1,103.7 (339.3) 1.00 (0.99–1.00) 0.143
Aspartate transaminase (IU/L) 1,307 50.1 (28.4) 81 49.3 (24.1) 0.99 (0.99–1.01) 0.802
Alkaline phosphatase (IU/L) 1,310 265.6 (124.2) 81 276.7 (152.8) 1.00 (0.99–1.00) 0.442
Association between mortality and laboratory measurements at enrollment was explored using logistic regression.
doi:10.1371/journal.pone.0014699.t003
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Low hemoglobin at enrollment was associated with mortality as
has been previously reported elsewhere[4,7,17,27,28]. There are
limited options for interventions, with blood transfusion and
Hydroxyurea being the two recommended therapies. Blood
transfusion has been found to be beneficial in SCA with stroke,
acute chest syndrome and peri-operatively in the West[29]. In
Africa, it is mainly used for treatment of acute anemia in SCA[29–
30], since there are considerable limitations of blood transfusion in
Africa such as inadequate blood supply, risk of transmission of
infections and alloimmunization. There is limited evidence to guide
rational use of blood in Africa as well as studies to assess its impact
on mortality. The alternative therapy is Hydroxyurea which
increases hemoglobin and HbF levels, reduces hemolysis and blood
transfusion requirement and has been effective in reducing
mortality[31]. The association between HbF and death in our
cohort was not significant, which may be due to a ‘healthy survivor
effect’; with the cohort consisting of patients with high HbF and
therefore being protected from mortality while those with low HbF
have succumbed to early mortality. Better understanding of the
burden and pathophysiology of anemia in SCA and the role of HbF
in SCA in this setting could guide interventions.
There is increasing evidence of the role of hemolysis in
pathogenesis of severe clinical complications in SCA, such as
pulmonary hypertension and stroke[5,32]. In this study we did not
find an association between hemolysis and death. Although total
bilirubin was an independent predictor, there was no association
with other hemolytic markers such as unconjugated bilirubin,
lactate dehydrogenase, aspartate transaminase and reticulocyte
count. The lack of an association between hemolysis and mortality
in this setting may be because hemolysis and the hyperhemolysis
phenotype are not common in Africa[33] or those with this
phenotype died before recruitment into this cohort. Furthermore,
most of the studies that have shown this association were in
adults[5]; the most recent study by Taylor et al, examined SCA
patients over 30 years[32]. Since only 11% of our study population
was above 20 years at enrollment, further studies are needed to
examine the role of hemolysis, using direct measurement of free
hemoglobin and comparison of markers during steady-state and
acute episodes.
This cohort highlights key areas to improve survival in SCA and
has identified gaps to guide further research. Over 85% of patients
enrolled into our clinic-based cohort survived, suggesting that SCA
patients in Africa are surviving beyond childhood. However, SCA
patients have a high mortality based on mortality and median
survival from this study. The estimated birth prevalence of SCA in
Tanzania is 7/1000[1,34]. If one assumes that this is representa-
tive of the urban population of Dar-es-Salaam, the population
prevalence of the SCA patients attending the hospital is a
maximum of 3.5/1,000. This leaves 50% of the SCA population
unaccounted for and it is not known to what extent this reflects
relatively well individuals not attending hospital, as opposed to loss
due to premature death. The median survival in SCA patients in
this cohort, comprising mainly older children and adults, was 33
years; which is 19 years less than life expectancy at birth (52 years)
in Tanzania[35] and is also markedly lower than for SCA patients
(40–60 years) in the USA[4] and Jamaica[9]. This median survival
of SCA is most likely an overestimate, as it does not capture the
individuals who died before diagnosis, or those who were lost to
follow up. Modell et al, estimated that 6 million Africans would be
living with SCA if average survival of affected children reaches half
the African norm[36]. The burden of disease to individuals,
communities and health systems has not been quantified, but these
patients will suffer from anemia, painful crises, infections, stroke
and other complications[2] and will require life-long care. It is also
of note that 12% of those enrolled into the cohort were lost to
follow-up and only 23% of deaths occurred in the hospital.
Attendance may be improved with health education to SCA
patients and their caregivers on the importance of regular follow-
up and comprehensive care. This finding also highlights the need
to develop clear guidelines of health services for SCA at home and
within health facilities in the community. We identified risk factors
for mortality, which should allow targeting of interventions to high
risk patients. Although most studies use steady-state laboratory
values (average well-visit routine measurements)[3,4] in this study
we used factors at enrollment visit, as SCA patients in Africa may
be seen at a health facility only once and most deaths occurred
outside MNH. Finally, although the mortality was highest in the
young children, this is most likely an underestimate as many
Figure 2. Survival of SCA during the study, stratified by level of hemoglobin at enrollment.
doi:10.1371/journal.pone.0014699.g002
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children are likely to have died before they could be referred to the
hospital clinic or diagnosed with SCA.
This study provides a description of mortality rates in SCA
amongst a hospital-based cohort in Dar-es-Salaam, Tanzania. As
expected, there is a high mortality in SCA, with children
significantly more affected. Although we have provided data that
will guide initial policies, the study has highlighted the areas for
further research. We propose that priority should be given to the
establishment of NBS to detect SCA patients at birth and allow
active prevention of infection. A birth cohort will also provide
accurate survival data and information on causes of morbidity and
mortality in early childhood. Furthermore, since anemia was
associated with mortality, detailed studies to identify causes and
clinical trials to determine appropriate interventions to ameliorate
anemia are needed.
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